JP2018531260A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531260A5 JP2018531260A5 JP2018519382A JP2018519382A JP2018531260A5 JP 2018531260 A5 JP2018531260 A5 JP 2018531260A5 JP 2018519382 A JP2018519382 A JP 2018519382A JP 2018519382 A JP2018519382 A JP 2018519382A JP 2018531260 A5 JP2018531260 A5 JP 2018531260A5
- Authority
- JP
- Japan
- Prior art keywords
- genetically engineered
- hematopoietic cell
- human hematopoietic
- engineered human
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 24
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 11
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 108091033409 CRISPR Proteins 0.000 claims 5
- 238000010354 CRISPR gene editing Methods 0.000 claims 5
- 108091026890 Coding region Proteins 0.000 claims 3
- 108091092724 Noncoding DNA Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108700010039 chimeric receptor Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 claims 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022010861A JP7680384B2 (ja) | 2015-10-16 | 2022-01-27 | 系統特異的抗原の阻害のための組成物および方法 |
| JP2024205201A JP2025028963A (ja) | 2015-10-16 | 2024-11-26 | 系統特異的抗原の阻害のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242685P | 2015-10-16 | 2015-10-16 | |
| US62/242,685 | 2015-10-16 | ||
| PCT/US2016/057339 WO2017066760A1 (en) | 2015-10-16 | 2016-10-17 | Compositions and methods for inhibition of lineage specific antigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022010861A Division JP7680384B2 (ja) | 2015-10-16 | 2022-01-27 | 系統特異的抗原の阻害のための組成物および方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018531260A JP2018531260A (ja) | 2018-10-25 |
| JP2018531260A6 JP2018531260A6 (ja) | 2018-12-13 |
| JP2018531260A5 true JP2018531260A5 (https=) | 2019-11-28 |
| JP7017506B2 JP7017506B2 (ja) | 2022-02-08 |
Family
ID=58518249
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519382A Active JP7017506B2 (ja) | 2015-10-16 | 2016-10-17 | 系統特異的抗原の阻害のための組成物および方法 |
| JP2022010861A Active JP7680384B2 (ja) | 2015-10-16 | 2022-01-27 | 系統特異的抗原の阻害のための組成物および方法 |
| JP2024205201A Ceased JP2025028963A (ja) | 2015-10-16 | 2024-11-26 | 系統特異的抗原の阻害のための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022010861A Active JP7680384B2 (ja) | 2015-10-16 | 2022-01-27 | 系統特異的抗原の阻害のための組成物および方法 |
| JP2024205201A Ceased JP2025028963A (ja) | 2015-10-16 | 2024-11-26 | 系統特異的抗原の阻害のための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US10137155B2 (https=) |
| EP (2) | EP3362472B1 (https=) |
| JP (3) | JP7017506B2 (https=) |
| CN (2) | CN108290939B (https=) |
| AU (2) | AU2016337525B2 (https=) |
| CA (1) | CA3001859A1 (https=) |
| ES (1) | ES2962651T3 (https=) |
| IL (3) | IL258491B2 (https=) |
| MX (2) | MX2018004546A (https=) |
| WO (1) | WO2017066760A1 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10201606B2 (en) | 2014-11-26 | 2019-02-12 | Miltenyi Biotec Gmbh | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| AU2016337525B2 (en) | 2015-10-16 | 2022-01-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| WO2017079400A1 (en) * | 2015-11-04 | 2017-05-11 | The Trustees Of The University Of Pennsylvania | Methods and compositions for gene editing in hematopoietic stem cells |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| RU2019130504A (ru) * | 2017-02-28 | 2021-03-30 | Вор Байофарма, Инк. | Композиции и способы ингибирования линиеспецифических белков |
| US11718659B2 (en) | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
| KR102320280B1 (ko) * | 2018-05-31 | 2021-11-29 | 주식회사 센트릭스바이오 | CD300c의 발현 억제제 또는 활성 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물 |
| US20210246472A1 (en) * | 2018-08-21 | 2021-08-12 | Sigma-Aldrich Co. Llc | Down-regulation of the cytosolic dna sensor pathway |
| WO2020051013A2 (en) * | 2018-08-24 | 2020-03-12 | The Trustees Of Columbia University In The City Of New York | Anti-cd33 and nkg2d ligand chimeras for treatment of myeloid malignancies |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| CN113194966A (zh) * | 2018-10-03 | 2021-07-30 | 柰裴斯生命科学公司 | 抗cd79抗体及其应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| BR112021008041A2 (pt) * | 2018-11-07 | 2021-08-10 | Crispr Therapeutics Ag | terapia contra o câncer com células imunitárias anti-cd33 |
| BR112021014010A2 (pt) * | 2019-01-16 | 2021-09-21 | The Trustees Of Columbia University In The City Of New York | Composições e métodos para inibição de antígenos linhagem-específicos |
| AU2020216780B2 (en) * | 2019-01-28 | 2025-05-08 | Multitude Therapeutics Inc. | Antibodies specific to CD44 |
| CN109777784B (zh) * | 2019-02-22 | 2021-12-31 | 上海尚泰生物技术有限公司 | 一种增强向肿瘤部位迁移的嵌合抗原受体载体构建方法与应用 |
| AU2020280103A1 (en) | 2019-05-23 | 2021-12-23 | Vor Biopharma Inc. | Compositions and methods for CD33 modification |
| WO2020264211A1 (en) * | 2019-06-26 | 2020-12-30 | Memorial Sloan Kettering Cancer Center | Anti-cd33 antibodies for treating cancer |
| AU2020338011A1 (en) | 2019-08-28 | 2022-03-10 | Vor Biopharma Inc. | Compositions and methods for CLL1 modification |
| WO2021041977A1 (en) | 2019-08-28 | 2021-03-04 | Vor Biopharma, Inc. | Compositions and methods for cd123 modification |
| WO2021081244A1 (en) * | 2019-10-22 | 2021-04-29 | Fred Hutchinson Cancer Research Center | Base editor-mediated cd33 reduction to selectively protect therapeutic cells |
| WO2022250433A1 (ko) * | 2021-05-24 | 2022-12-01 | 주식회사 센트릭스바이오 | Cd300c 항원 또는 그의 수용체에 특이적으로 결합하는 키메라 항원 수용체 |
| AU2021239929A1 (en) * | 2020-03-16 | 2022-10-13 | Crispr Therapeutics Ag | T-cell bispecific binding proteins |
| CN116157135A (zh) * | 2020-06-03 | 2023-05-23 | 纽约市哥伦比亚大学理事会 | 使用基于crispr的碱基编辑器系统抑制谱系特异性抗原的组合物和方法 |
| US20240238344A1 (en) | 2020-08-28 | 2024-07-18 | Vor Biopharma Inc. | Compositions and methods for cd123 modification |
| WO2022047168A1 (en) | 2020-08-28 | 2022-03-03 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| EP4210832A1 (en) | 2020-09-14 | 2023-07-19 | Vor Biopharma, Inc. | Chimeric antigen receptors for treatment of cancer |
| WO2022056459A1 (en) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions and methods for cd5 modification |
| JP2023541457A (ja) | 2020-09-14 | 2023-10-02 | ブイオーアール バイオファーマ インコーポレーテッド | Ｃｄ３８修飾のための化合物および方法 |
| WO2022061115A1 (en) | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| US20230364233A1 (en) | 2020-09-28 | 2023-11-16 | Vor Biopharma Inc. | Compositions and methods for cd6 modification |
| WO2022072643A1 (en) | 2020-09-30 | 2022-04-07 | Vor Biopharma Inc. | Compositions and methods for cd30 gene modification |
| WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
| EP4243858A1 (en) * | 2020-11-13 | 2023-09-20 | Vor Biopharma Inc. | Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| JP2024502820A (ja) * | 2020-12-31 | 2024-01-23 | ブイオーアール バイオファーマ インコーポレーテッド | Ｃｄ３４遺伝子改変のための組成物及び方法 |
| CN120249215A (zh) * | 2021-04-27 | 2025-07-04 | 上海驯鹿生物技术有限公司 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
| CA3220226A1 (en) * | 2021-05-24 | 2022-12-01 | Jae-Won Jeon | Chimeric antigen receptor specifically binding to cd300c antigen or receptor thereof |
| WO2023283585A2 (en) | 2021-07-06 | 2023-01-12 | Vor Biopharma Inc. | Inhibitor oligonucleotides and methods of use thereof |
| EP4376877A2 (en) | 2021-07-29 | 2024-06-05 | Vor Biopharma Inc. | Chimeric antigen receptors for treatment of cancer |
| AU2022324093A1 (en) | 2021-08-02 | 2024-02-08 | Vor Biopharma Inc. | Compositions and methods for gene modification |
| WO2023043858A1 (en) * | 2021-09-14 | 2023-03-23 | Vor Biopharma Inc. | Compositions and methods for multiplex base editing in hematopoietic cells |
| JP2024543369A (ja) | 2021-11-09 | 2024-11-21 | ブイオーアール バイオファーマ インコーポレーテッド | Ｅｍｒ２修飾のための化合物及び方法 |
| AU2023251040A1 (en) | 2022-04-04 | 2024-10-17 | Vor Biopharma Inc. | Compositions and methods for mediating epitope engineering |
| CA3248167A1 (en) | 2022-04-11 | 2023-10-19 | Vor Biopharma Inc. | LIAISON AGENTS AND THEIR METHODS OF USE |
| CN114778857B (zh) * | 2022-06-17 | 2022-08-23 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | 检测非造血系统肿瘤的试剂组合物及其应用 |
| WO2024015925A2 (en) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
| WO2024168312A1 (en) | 2023-02-09 | 2024-08-15 | Vor Biopharma Inc. | Methods for treating hematopoietic malignancy |
| WO2024238565A1 (en) | 2023-05-15 | 2024-11-21 | Vor Biopharma Inc. | Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
| CN117946270B (zh) * | 2023-12-26 | 2025-02-11 | 华润生物医药有限公司 | 抗cd93抗体及其用途 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| AU648261B2 (en) | 1989-08-18 | 1994-04-21 | Novartis Vaccines And Diagnostics, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1993025216A1 (en) * | 1992-06-08 | 1993-12-23 | Becton, Dickinson And Company | Human primitive stem cells |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| CA2137361A1 (en) | 1992-06-10 | 1993-12-23 | W. French Anderson | Vector particles resistant to inactivation by human serum |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| AU687117B2 (en) | 1993-10-25 | 1998-02-19 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5756910A (en) | 1996-08-28 | 1998-05-26 | Burgett, Inc. | Method and apparatus for actuating solenoids in a player piano |
| WO1998022588A2 (en) | 1996-11-20 | 1998-05-28 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| WO2008086529A2 (en) | 2007-01-11 | 2008-07-17 | Yale University | Compositions and methods for targeted inactivation of hiv cell surface receptors |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| MX2012004522A (es) | 2009-10-19 | 2012-05-08 | Tristem Trading Cyprus Ltd | Tratamiento que usa celulas adultas maduras reprogramadas. |
| AU2011281062B2 (en) | 2010-07-21 | 2015-01-22 | Board Of Regents, The University Of Texas System | Methods and compositions for modification of a HLA locus |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2655624B1 (en) | 2010-12-23 | 2017-11-29 | Biogen MA Inc. | Linker peptides and polypeptides comprising same |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| AU2013329186B2 (en) | 2012-10-10 | 2019-02-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| EP3087101B1 (en) * | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| WO2015121454A1 (en) * | 2014-02-14 | 2015-08-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| CN106795221B (zh) | 2014-04-03 | 2022-06-07 | 塞勒克提斯公司 | 用于癌症免疫治疗的cd33特异性嵌合抗原受体 |
| AU2015244039B2 (en) | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| KR20200138445A (ko) * | 2014-04-24 | 2020-12-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용 |
| TWI719942B (zh) | 2014-07-21 | 2021-03-01 | 瑞士商諾華公司 | 使用ｃｄ３３嵌合抗原受體治療癌症 |
| US10201606B2 (en) * | 2014-11-26 | 2019-02-12 | Miltenyi Biotec Gmbh | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| EP3288569A4 (en) | 2015-04-29 | 2018-12-19 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
| CA2986310A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| AU2016337525B2 (en) | 2015-10-16 | 2022-01-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| WO2017079400A1 (en) | 2015-11-04 | 2017-05-11 | The Trustees Of The University Of Pennsylvania | Methods and compositions for gene editing in hematopoietic stem cells |
| KR20230148844A (ko) | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| US11499168B2 (en) | 2016-04-25 | 2022-11-15 | Universitat Basel | Allele editing and applications thereof |
| LT3535392T (lt) | 2016-11-02 | 2024-04-25 | Universität Basel | Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje |
| RU2019130504A (ru) | 2017-02-28 | 2021-03-30 | Вор Байофарма, Инк. | Композиции и способы ингибирования линиеспецифических белков |
| US11718659B2 (en) | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
-
2016
- 2016-10-17 AU AU2016337525A patent/AU2016337525B2/en active Active
- 2016-10-17 CA CA3001859A patent/CA3001859A1/en active Pending
- 2016-10-17 IL IL258491A patent/IL258491B2/en unknown
- 2016-10-17 CN CN201680067189.3A patent/CN108290939B/zh active Active
- 2016-10-17 MX MX2018004546A patent/MX2018004546A/es unknown
- 2016-10-17 ES ES16856410T patent/ES2962651T3/es active Active
- 2016-10-17 WO PCT/US2016/057339 patent/WO2017066760A1/en not_active Ceased
- 2016-10-17 JP JP2018519382A patent/JP7017506B2/ja active Active
- 2016-10-17 CN CN202211723888.2A patent/CN116712535A/zh active Pending
- 2016-10-17 EP EP16856410.2A patent/EP3362472B1/en active Active
- 2016-10-17 IL IL300420A patent/IL300420B2/en unknown
- 2016-10-17 EP EP23187118.7A patent/EP4265633A3/en active Pending
-
2017
- 2017-07-20 US US15/655,432 patent/US10137155B2/en active Active
-
2018
- 2018-04-12 MX MX2024000739A patent/MX2024000739A/es unknown
- 2018-10-29 US US16/174,089 patent/US10660919B2/en active Active
- 2018-10-29 US US16/174,005 patent/US10786535B2/en active Active
-
2019
- 2019-06-25 US US16/451,934 patent/US10668103B2/en active Active
- 2019-06-25 US US16/451,906 patent/US20190314418A1/en active Pending
-
2020
- 2020-05-19 US US16/877,932 patent/US10912799B2/en active Active
-
2021
- 2021-04-29 US US17/243,987 patent/US20210252073A1/en active Pending
- 2021-12-15 IL IL289046A patent/IL289046A/en unknown
- 2021-12-23 AU AU2021290320A patent/AU2021290320A1/en not_active Abandoned
-
2022
- 2022-01-27 JP JP2022010861A patent/JP7680384B2/ja active Active
-
2024
- 2024-11-26 JP JP2024205201A patent/JP2025028963A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531260A5 (https=) | ||
| Zhu et al. | Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity | |
| JP7168641B2 (ja) | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 | |
| Tsao et al. | CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis | |
| Ruggeri et al. | Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells | |
| LTPA2022520I1 (https=) | ||
| JP2023530408A5 (https=) | ||
| JP2022517618A5 (https=) | ||
| PH12017501732A1 (en) | Therapeutic antibodies and their uses | |
| JP2018510881A5 (https=) | ||
| JOP20190116A1 (ar) | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها | |
| NZ774111A (en) | Antibodies binding to cd3 | |
| HRP20171577T1 (hr) | Uporaba t stanica modificiranih himernim receptorom za antigen za liječenje karcinoma | |
| EA201891428A1 (ru) | Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли | |
| MY187624A (en) | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor | |
| FI3736291T3 (fi) | Anti-fcrh5-vasta-aineita | |
| PE20180249A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| AU2019277660A1 (en) | Materials and methods for treating cancer | |
| Bugide et al. | Epigenetic mechanisms dictating eradication of cancer by natural killer cells | |
| PH12020551187A1 (en) | Bispecific antigen-binding molecules and methods of use | |
| CN113194715A (zh) | 用于治疗癌症的材料和方法 | |
| MX2023009211A (es) | Anticuerpos biespecificos con pares de carga y usos de los mismos. | |
| Balduzzi et al. | Acute lymphoblastic leukaemia in the youngest: haematopoietic stem cell transplantation and beyond | |
| Chen et al. | Stereotactic ablative radiotherapy and FAPα-based cancer vaccine suppresses metastatic tumor growth in 4T1 mouse breast cancer | |
| Masu et al. | Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression |